脐带间充质干细胞移植治疗初发1型糖尿病

背景：研究证实,新诊断的1型糖尿病患者,接受自体造血干细胞治疗后,绝大多数患者胰岛β细胞功能增强,不依赖胰岛素的时间也延长。目的：观察人脐带间充质干细胞移植治疗初发1型糖尿病的临床疗效。方法：选择12例病程〈3个月的初发1型糖尿病患者,其中6例行人脐带间充质干细胞和胰岛素治疗,另外6例行单纯胰岛素治疗。移植前及移植9个月后分别监测空腹及餐后血糖、胰岛素用量、C肽、HbA1c的变化和记录不良反应。结果与结论：随访9个月,干细胞治疗组的空腹血糖,糖化血红蛋白及C肽水平都有明显的改善,而对照组C肽水平明显下降,其他指标变化不明显。提示,人脐带间充质干细胞治疗初发1型糖尿病疗效良好。

Umbilical cord mesenchymal stem cells transplantation for newly-onset type 1 diabetes

BACKGROUND：Autologous hematopoietic stem cells transplantation can enhance function of beta cells of islet and prolong time independent of insulin.OBJECTIVE：To observe the clinical efficacy of human umbilical cord mesenchymal stem cells（hUCMSCs） transplantation in treatment of newly-onset type 1 diabetes.METHODS：A total of 12 patients with newly-onset type 1 diabetes mellitus（less than 3 months） were selected.Six cases were treated by hUCMSCs transplantation and insulin,and the other 6 were treated by insulin alone.Before and 9 months after transplantation,fasting and postprandial blood glucose,insulin dosage,C peptide,HbA1c changes and adverse events were measured.RESULTS AND CONCLUSION：Patients were followed up for 9 months.Fasting blood glucose,HbA1c and C peptide levels were significantly improved in stem cell therapy group compared with control group.In addition to significantly reduced C peptide levels,other indexes remained unchanged in control group.Results showed that hUCMSCs transplantation has positive effects on treatment of newly-onset type l diabetes.